Patient adherence to and tolerability of treatment with metformin extended-release formulation in patients with type 2 diabetes. GLUCOMP study by Strojek, Krzysztof et al.
 ORIGINAL ARTICLE ISSN 2450–7458
15www.dk.viamedica.pl
Address for correspondence:  
prof. dr hab. n. med. Krzysztof Strojek 
Oddział Kliniczny Chorób Wewnętrznych, Diabetologii i Schorzeń 
Kardiometabolicznych Śląskie Centrum Chorób Serca 
ul. M. Curie-Skłodowskiej 9, 41–800 Zabrze
Phone: +48 (32) 37 33 864
Fax: +48 (32) 278 43 34
e-mail: kstrojek@sum.edu.pl 
Clinical Diabetology 2016, 5, 1, 15–21
DOI: 10.5603/DK.2016.0003
Translation: dr med. Jędrzej Toczko,  
dr hab. med. Anna Korzon-Burakowska
Received: 04.12.2015  Accepted: 28.01.2016 
Krzysztof Strojek1, Anna Kurzeja2, Ulrike Gottwald-Hostalek3  
on behalf of the GLUCOMP Research Group
1Oddział Kliniczny Chorób Wewnętrznych, Diabetologii i Schorzeń Kardiometabolicznych, Śląskie Centrum Chorób Serca w Zabrzu,  
Śląski Uniwersytet Medyczny w Katowicach 
2Merck Sp. z o.o., Warszawa 
3Merck KGaA, Darmstadt, Niemcy 
Patient adherence to and tolerability  
of treatment with metformin  
extended-release formulation in patients 
with type 2 diabetes. GLUCOMP study
ABSTRACT
Introduction. Appropriate treatment of diabetes re-
quires regular intake of recommended drugs. Multifac-
torial therapy, which necessitates the concomitant use 
of many medications, may decrease patient adherence. 
The purpose of the study was to assess type 2 diabetic 
patients’ adherence to and tolerability of metformin 
extended-release formulation in the outpatient setting.
Materials and methods. This non-interventional study 
was conducted in a group of 4737 patients [including 
2468 (52%) women] with mean age of 60.6 ± 9.4 years, 
diabetes duration of 5.6 ± 4.4 years, duration of treat-
ment with metformin extended release formulation of 
8.3 ± 12 months at an average dose of 1667 ± 350 mg. 
The study enrolled patients aged over 18 years with 
type 2 diabetes if they were treated with metformin ex-
tended-release formulation at a dose of 1500–2000 mg 
for less than 1 year prior to the study enrollment. The 
exclusion criteria included: pregnancy, breast-feeding 
and any contraindications for metformin treatment. 
Treatment adherence was assessed by a tablet count 
(percentage of prescribed tablets taken) and using 
the Morisky-Green scale. Treatment adherence was 
defined as follows: excellent patient adherence if 
> 90% of prescribed tablets were taken; good: 76–90%; 
moderate: 51–75%; poor: ≤ 50%. Treatment tolerability 
was also evaluated based on the medical history fo-
cused on gastrointestinal symptoms, as well as patient 
preference for using specific types of metformin. Other 
patient data, clinical data and laboratory test results 
were recorded at the beginning of the study and after 
3 months.
Results. After 3 months of treatment with metformin 
extended release formulation 96% of study subjects 
demonstrated excellent or good adherence. Treatment 
adherence was significantly lower with 2 or 3 con-
comitant medications as compared to one (p < 0.001). 
Adverse events occurred in 715 patients (15% out of 
4758 patients undergoing safety analysis). The oc-
currence of adverse events significantly decreased 
treatment adherence (p < 0.001). Approximately 90% 
of patients declared they had preferred the use of 
metformin extended-release formulation.
Conclusions. Metformin extended-release formulation 
is a suitable, well tolerated therapeutic option which 
helps to obtain good patient cooperation based on 
good adherence. (Clin Diabet 2016; 5, 1: 15–21)
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Introduction
Epidemiological data shows increasing incidence of 
diabetes [1]. It is primarily an increase in type 2 diabetes 
patients numbers [2]. The main concern in diabethol-
ogy is the occurrence of late complications, being the 
cause of premature death, disability and decline in 
quality of life [3]. Up-to-date diabetes treatment aimed 
at preventing complications includes the so called 
‘multifactorial therapy’, consisting of normalization 
of glycaemia, lipemia and arterial blood pressure [4]. 
A treatment which provides reaching optimal blood 
glucose levels is one of the key elements of an effective 
therapy [5]. The typical progressive course of type 2 
diabetes determines the need for gradual intensifica-
tion of treatment, raging from diet and oral medica-
ments in mono- and polytherapy, to insulin therapy at 
the other end of the spectrum [6, 7]. Metformin plays 
a prominent part amongst oral antiglycemic medica-
ments, showing not only antiglycemic effects, but also 
additional cardioprotective properties which have been 
proven by prospective studies [8, 9]. In accordance 
with type 2 diabetes therapeutic guidelines for treating 
hyperglycaemia, metformin should be used at every 
stage of the treatment, provided that no contradic-
tions or intolerance symptoms occur [6, 7]. Metformin 
extended-release (Glucophage® XR) formulation is a re-
cently introduced drug form which, through adequate 
tablet construction, enables administering once a day 
[10]. Using this form of the drug is related to lower 
incidence of adverse events [11].
Level of adherence and regular drug intake are vital 
aspects of an effective antidiabetic therapy [12, 13].
The purpose of the study was to asses: 
 — adherence to therapeutic guidance;
 — tolerability (incidence of adverse events);
 — patients preference, concerning the metformin 
extended-release formulation use compared with 
standard metformin form in patients with type 2 
diabetes treated with metformin extended-release 
formulation (Glucophage® XR) in the outpatient 
setting.
Materials and methods
This non-interventional study was conducted in 
a group of 4737 patients, whose data was collected in 
601 study centers. 
Study inclusion criteria:
 — extended-release metformin (Glucophage® XR) 
treatment no longer than a year prior study inclusion;
 — age of 18 or older;
 — HbA1c blood test performed up to one year prior 
inclusion.
Study exclusion criteria:
 — any contraindications for metformin treatment;
 — pregnancy or breastfeeding;
 — no effective contraceptive therapy if of childbear-
ing age.
The conducted study consisted of two visits sepa-
rated with 3 months, with data collected using a Case 
Report Form (CRF):
 — general information — age, sex, BMI, duration of 
diabetes, duration of metformin extended-release 
formulation treatment;
 — medical history of diabetes complications and 
comorbidities such as arterial hypertension and 
dyslipidemia. The investigator ascertained arterial 
hypertension based on anamnesis and a routine 
blood pressure check during the first visit (blood 
pressure equal or greater than 140/90 mm Hg or 
antihypertensive therapy). The investigator ascer-
tained dyslipidemia based on anamnesis (incorrect 
blood lipid values or antilipemic therapy);
 — information on physical activity and education level. 
Type 2 diabetes education level was assessed by the 
investigator based on anamnesis data such as: type 
of received education ( self-education, education 
conducted by a nurse, a diabetic educator or a doc-
tor), weekly hours of education (1–2, 3–4, 5–6, > 6), 
how many times a week (daily, 2–3 times a week, 
once a week or less) and in a subjective, 4-level scale: 
unsatisfactory, sufficient, good, excellent;
 — current antiglycemic treatment;
 — glycaemia control (fasting glycaemia, postprandial 
glycaemia, HbA1c);
 — metformin intolerance symptoms;
 — treatment adherence, by numbers of prescribed 
and taken tablets of metformin extended-release 
formulation.
The primary endpoint of the study was treatment 
adherence during metformin extended-release formu-
lation therapy. Treatment adherence was assessed by 
a tablet count (percentage of prescribed tablets taken). 
Treatment adherence was defined as follows: excellent 
adherence if > 90% of prescribed tablets were taken, 
good: 76–90%, moderate: 51–75%, poor: £ 50%.
Treatment adherence was also assessed using the 
Morisky-Green scale [14], grading it as low, medium 
or high. These categories were assigned based on 
a score, resulting from a 4 step questionnaire (yes — 1 
point, no — 0 points):
 — Do you ever forget to take your medicine?
 — Are you careless at times about taking your medicine?
 — When you feel better do you sometimes stop tak-
ing your medicine?
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 — Sometimes if you feel worse when you take the 
medicine, do you stop taking it? 
Patients assigned to high treatment adherence 
group answered negatively on all of the questions 
(0 points); these assigned to medium treatment adher-
ence group received 1–2 points, and to low treatment 
adherence group: 3–4 points. 
The secondary endpoint of the study was an as-
sessment of patients’ preference concerning extended-
-release metformin compared with retrospective data 
describing standard drug form usage and an evaluation 
of tolerance of currently used metformin extended-
-release formulation.
Only authorized personnel had access to identifica-
tion enabling information, if verification was necessary. 
Legal regulations related to personal data and privacy 
protection were complied with while gathering, for-
warding, processing and storing patients’ data. 
A descriptive statistical analysis was performed. 
Mean values, standard deviations and quartiles were 
calculated. Correlation analysis and c2 test were per-
formed for the primary endpoint with following values: 
prescribed tablets count, taken tablets count, physical 
activity, gastrointestinal intolerance, diabetes duration 
and antidiabetic treatment duration.
Results
The study enrolled 4737 patients [including 2468 
(52%) women] with mean age of 60.6 ± 9.4 years, dia-
betes duration of 5.6 ± 4.4 years, duration of treatment 
with metformin extended-release formulation of 8.3 ± 
± 12 months at an average dose of 1667 ± 350 mg. 
Average BMI of patients enrolled in the study was 30.5 ± 
± 4.3. The profile of the study group is presented 
in Table 1.
Amongst enrolled patients 50% had coexisting 
macroangiopathy, microangiopathy was present in 
33%, arterial hypertension in 88%; 83% had dyslip-
idemia. 15% of the group were active smokers, 26% 
former smokers. In the hypertensive patients group 
53% received 1 hypotensive drug as treatment, 5% 
received two drugs, 0,2% — 3 or more drugs.
Table 2 presents treatment adherence concerning 
diabetes treated with metformin extended-release for-
mulation based on a prescribed/taken tablets ratio. An 
overwhelming majority of patients presented excellent 
or good treatment adherence (96%). This table also 
displays treatment adherence concerning diabetes 
treated with extended-release metformin, estimated 
with the Morisky-Green scale. Results are similar to 
those obtained by the prescribed/taken tablet ratio 
method, showing over 90% of excellent or good treat-
ment adherence.
Treatment adherence concerning diabetes treated 
with extended-release metformin was dependent on: 
the number of tablets prescribed, number of other 
concomitant medications taken (taking more than 2 
drugs impaired treatment adherence), physical activity 
(patients with excellent treatment adherence reported 
Table 1. Demographics
n = 4737
Age (years)
Mean (SD) 60.6 (9.4)
Min., max. 21; 98
Sex
Female 2468 (52.1%)
Male 2269 (47.9%)
Body mass index [kg/m2]
Mean (SD) 30.5 (4.3)
Min., max. 17.3; 67.0
Nicotine use
Smoker 693 (14.6%)
Ex-smoker 1240 (26.2%)
Non-smoker 2804 (59.2%)
Education level
Excellent 346 (7.3%)
Good 1952 (41.2%)
Sufficient 2029 (42.8%)
Unsatisfactory 410 (8.7%)
Physical activity
Macroangiopathy
Microangiopathy
Arterial hypertension
Dyslipidemia
Fasting glycaemia [mg/dL]
> once a week 2237 (47.2%)
2378 (50.2%)
1559 (32.9%)
> 140/90 mm Hg 4165 (87.9%)
3922 (82.8%)
Mean (SD) 122 (24)
Min., max. 60; 308
Postpriandal glycaemia 
[mg/dL]
Mean (SD) 152 (32)
Min., max. 74; 488
HbA1c (%) Mean (SD) 7.05 (0.86)
Min., max. 4.7; 13.8
SD — standard deviation
Table 2. Levels of treatment adherence concerning 
extended-release metformin based on a tablet count and 
Morisky-Green scale
Treatment adherence n %
Tablet count
Excellent 4063 85.8
Good 505 10.7
Moderate 128 2.7
Poor 40 0.8
Morisky-Green scale
High 3705 78.2
Medium 895 18.9
Low 137 2.9
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being physically active more than once a week). 
Further analysis proved that lack of gastrointestinal 
adverse events resulted in an increase in treatment 
adherence, while longer diabetes and metformin 
treatment duration were correlated with lower treat-
ment adherence. 
Analysis of patients’ preference regarding metfor-
min extended-release formulation and conventional 
form showed that 90% of patients preferred extended-
release form, 9% showed no preference at all and 1% 
preferred standard metformin form.
Table 3 shows incidence of adverse events during 
the observation period. Adverse events were noted in 
715 patients (15% of 4737 patients who were subject 
to safety analysis). Most frequent adverse events that 
occurred during the study were: nausea (261, 5.5%), 
diarrhea (259, 5.4%) and abdominal pain (233, 4.9%).
Table 4 displays treatment adherence in relation 
to the amount of concomitant medicaments. Excellent 
treatment adherence assessed by metformin tablets 
used by the patient was observed in 87% of patients 
taking only 1 drug, 86% taking 2 drugs and 75% of 
patients taking 3 drugs (p < 0,001). Percentages pa-
tients of excellent treatment adherence assessed with 
the Morisky-Green scale were 83%, 75% and 65% ac-
cordingly (p < 0.001).
Table 5 presents treatment adherence in relation to 
observed gastrointestinal adverse events. A significant 
decrease in treatment adherence was observed when 
these effects occurred. High percentage of treatment 
adherence was ascertained in 87% of patients without 
gastrointestinal adverse events and 63% of patients 
with them while using the tablet count method, 
whereas Morisky-Green scale results were accordingly 
80% vs. 54%.
Discussion
Metformin is the drug of choice in pharmacological 
treatment of type 2 diabetes [15]. However, using stand-
ard metformin has a few restraints, such the need of 
taking it 2–3 times a day or very common gastrointestinal 
adverse events, namely nausea, vomiting, diarrhea, ab-
dominal pain or appetite loss [16]. Treatment adherence 
is a vital issue especially in regard of chronic diseases, 
such as diabetes [17]. Extended-release metformin pro-
vides a chance of increasing treatment adherence and 
improve gastrointestinal tolerance of the drug. 
This study demonstrates excellent treatment adher-
ence related to metformin extended-release formulation 
(Glucophage® XR). Relatively good treatment adherence 
was also displayed by patients using other concomitant 
drugs and patients experiencing adverse events. Thera-
Table 3. Incidence of adverse events
Patients with at 
least one adverse 
events present
% of all adverse 
events
% of patients with 
adverse events
% all  
patients
n = 715 n = 4737
Nausea 261 28.3 36.50 5.49
Diarrhea 259 28.1 36.22 5.47
Abdominal pain 233 25.2 32.59 4.92
Apetite reduction 121 13.1 16.92 2.55
Bloating 15 1.6 2.10 0.32
Bomiting 12 1.3 1.68 0.25
Apetite loss 8 0.9 1.12 0.17
Gastrointestinal symptoms 4 0.4 0.56 0.08
Transient abdominal pains 1 0.1 0.14 0.02
Indigestion 1 0.1 0.14 0.02
Non-specific gastrointestinal symptoms 1 0.1 0.14 0.02
Heartburn 1 0.1 0.14 0.02
Unpleasant aftertaste 1 0.1 0.14 0.02
Unlpleasant taste 1 0.1 0.14 0.02
Constipation 1 0.1 0.14 0.02
Puritus 1 0.1 0.14 0.02
Vertigo 1 0.1 0.14 0.02
Viral infection 1 0.1 0.14 0.02
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peutic guidance is in many cases followed correctly by 
the patients, reaching highest efficiency while using 1 or 
2 drugs. A decrease in adherence occurring with coexist-
ing adverse events indicates the need for adverse events 
monitoring throughout whole metformin treatment.
Presented study was conducted in 601 randomly 
chosen centers in Poland amongst 4737 patients 
treated with extended-release metformin. Given the 
randomness of center enrollment and the fact that 
patients where successively included into the study 
during control visits, it may be assumed that the study 
is representative of the metformin treated patient 
population. Structurally, the study consisted of two 
visits: initial visit, when general information was col-
lected concerning patients profile, treatment, metabolic 
control or adverse events occurrence. Analysis was 
performed with data acquired during the final visit 
after 3 months of observation, assumption being that 
reliable results involving treatment adherence and 
calculated from prescribed/taken tablet ratio can only 
be ascertained within a defined timeline. The 3 months 
observation period enabled capturing all key stages of 
correct treatment adherence, starting with buying the 
prescribed drug, then beginning the treatment, up to 
its continuation after the whole pack had been taken. 
There are different ways of assessing treatment 
adherence [18]. This study was conducted using a dual 
method. Firstly, it was calculated by prescribed and 
taken tablet count during a 3 month observation pe-
riod, also referred to as the time between the first and 
the last visit. However, this approach may be a source 
of inaccuracies, as it is difficult to estimate the tablet 
Table 4. Levels of treatment adherence concerning extended-release metformin according to the number of drugs taken, 
based on a tablet count and Morisky-Green scale
Treatment adherence Number of drugs taken Patients in total P (c2)
1 2 > 2
Tablet count
Patients in total 1994 2499 243 4736 < 0.001
Poor 16 (0.8%) 21 (0.8%) 3 (1.2%) 40 (0.8%)
Moderate 50 (2.5%) 56 (2.2%) 22 (9.1%) 128 (2.7%)
Good 191 (9.6%) 279 (11.2%) 35 (14.4%) 505 (10.7%)
Excellent 1737 (87.1%) 2143 (85.8%) 183 (75.3%) 4063 (85.8%)
Morisky-Green scale
Patients in total 1994 2500 243 4737 < 0.001
low 48 (2.4%) 75 (3.0%) 14 (5.8%) 137 (2.9%)
Moderate 296 (14.8%) 529 (21.2%) 70 (28.8%) 895 (18.9%)
High 1650 (82.7%) 1896 (75.8%) 159 (65.4%) 3705 (78.2%)
Table 5. Levels of treatment adherence concerning extended-release metformin according to gastrointestinal adverse 
events, based on a tablet count and Morisky-Green scale
Treatment adherence Gastrointestinal adverse events Patients in total P (c2)
No Yes
Tablet count
Patients in total 4046 690 4736 < 0.001
Poor 24 (0.6%) 16 (2.3%) 40 (0.8%)
Moderate 84 (2.1%) 44 (6.4%) 128 (2.7%)
Good 376 (9.3%) 129 (18.7%) 505 (10.7%)
Excellent 3562 (88%) 501 (72.6%) 4063 (85.8%)
Morisky-Green scale
Patients in total 4046 691 4737 < 0.001
Low 100 (2.5%) 37 (5.4%) 137 (2.9%)
Moderate 700 (17.3%) 195 (28.2%) 895 (18.9%)
High 3246 (80.2%) 459 (66.4%) 3705 (78.2%)
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count in everyday practice. For this reason, the results 
were validated with the Morisky-Green scale [14]. Ques-
tions included in it do not involve a timeline; therefore 
the patients’ answers may have been related not only 
to the analyzed period, but to the whole treatment of 
diabetes, as well as to all taken medicaments instead 
of only the investigated drug. In authors’ opinion, us-
ing two assessment methods simultaneously removes 
the inaccuracies and minimizes the risk of assessment 
error happening while using one method alone. It is 
important to highlight the fact that both methods 
indicated a high percentage of treatment adherence.
Some studies show that the level of treatment 
adherence correlates negatively with the number of 
tablets taken [19]. In the presented study we analyzed 
this parameter in relation to metformin , prescribed to 
be taken daily. However, mean dose of extended-release 
metformin taken by patients amounted to 1667 mg 
a day, which suggests that the vast majority of patients 
had to take more than one tablet. The results obtained 
indicate that high level of treatment adherence re-
mained in a meaningful negative correlation with the 
amount of tablets taken, although it must be noted 
that even with greater tablet numbers, it remained 
high (Tab. 4.) This demonstrates the need to emphasize 
reduction of tablet numbers, which can be achieved by 
i.e. using extended-release medications formulation.
Molsa et al. study analyzed treatment adherence 
in diabetic patients in the outpatient setting, based 
on the Morisky-Green scale [19]. The results shown 
a much higher adherence level amongst type 1 diabetes 
patients compared to type 2 diabetes patient. Amongst 
type 2 diabetes patients, in a population similar to 
presented study, no correlation was found between 
treatment adherence and body mass, diabetes duration 
or metabolic control. It is worth mentioning that Molsa 
et al. study categorized only 28% of patients as present-
ing high level treatment adherence. Higher percentages 
in the presented study seem to emerge from the fact 
that treatment adherence was only assessed concerning 
one medicament, not diabetes treatment as a whole.
Analysis of adverse events occurrence is a vital part 
of therapy effectiveness assessment. Literature data 
indicates that adverse events, mainly gastrointestinal, 
occur in 20–30% of patients treated with standard met-
formin and are dose dependant; however only 3–7% 
of patients withdrew the treatment [20]. In regard of 
metformin extended-release formulation, the adverse 
event incidence did not exceed 20%, while the propor-
tion of patients interrupting the treatment oscillated 
around 2% [21]. In the presented study the incidence of 
adverse events was distinctly lower. This resulted from 
the observational study methodology and including 
patients permanently treated with extended-release 
metformin medications, which allowed pre-selection 
and exclusion of patients who were forced to withdraw 
treatment because of the adverse events. This brings 
the conclusion that adverse events reported by patients 
were mild enough to continue the treatment. While 
interpreting the use of the drug in patients who pre-
sent adverse events, it must be noted that sometimes 
these effects occur later in time and patient may not 
associate it with the drug taken. This interference was 
demonstrated only by using patient observation form 
(CRF) containing detailed questions. However, the study 
results regarding treatment adherence indicate that 
presence of adverse events has a negative impact on it 
(Tab. 5). It must be noted that patients who experienced 
adverse effects still maintained a relatively high level of 
treatment adherence, which on the other hand points 
to a need of performing a more detailed anamnesis 
focused on adverse events at every visit, even in long 
term treatment, and possible treatment correction.
Conclusions
In conclusion, the study results indicate that 
metformin extended-release formulation is a good 
therapeutic option for acquiring patient compliance 
with high level of treatment adherence. 
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